Sonothera
Biotechnology company developing an ultrasound-guided nonviral gene therapy platform to provide patients with the next generation of genetic medicines, enabling targeted and repeatable gene delivery without viral vectors.
Notes
Sonothera is a biotechnology company developing an ultrasound-guided nonviral gene therapy platform. The company's technology aims to provide patients with the next generation of genetic medicines by enabling targeted gene delivery without the limitations of viral vectors.
The company's approach uses ultrasound to guide and enhance the delivery of genetic payloads to specific tissues. This nonviral approach offers several potential advantages:
- Repeatable dosing (unlike viral vectors which can trigger immune responses)
- Targeted delivery to specific tissues
- Reduced immunogenicity
- Potentially lower manufacturing costs
Sonothera's technology is based on foundational research from the laboratory of Mark Borden at the University of Colorado.
Team
- Mark Borden, Ph.D. - Co-founder & Chief Scientific Officer
- Professor at University of Colorado Boulder
- LinkedIn: linkedin.com/in/markborden
Additional Research Findings
- Ultrasound-guided gene delivery platform
- Nonviral gene therapy approach
- Repeatable dosing capability
- University of Colorado spinout
- Boulder, Colorado headquarters
- Founded in 2020
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |